Vatalanib
As of the edition of 20 October 2026, Vatalanib is a small molecule: went quiet in 2018; acts on CSF1R, FLT1 and FLT4 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 34, 8 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Blood and lymph; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B and 1 company-target row on route A because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Vatalanib.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company-target row is on route A because of Vatalanib.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 |
| Phase 2 | 22 | 15 | 0 | 7 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 34 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2002 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2004 to now |
| Bayer | Lead sponsor of trials | 2005 to now |